RxDoctor Payments DataLook up a doctor →

Jessica Amborski

Physician Assistant · Orchard Park, NYNPI 1508144288

Payments from drug & device makers

$26,603in general payments, 2019–2025

Across 1,249 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$3K
  • AbbVie$3K
  • Amgen$2K
  • UCB, Inc.$1K
  • MDD US Operations, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $15K from 54 others

What the payments were for

  • Travel & lodging$1,0674%
  • Food & beverage$25,44696%
  • Education$900%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.60$3,051
AbbVie(2 entities)156$2,648
Amgen(2 entities)88$1,503
UCB, Inc.64$1,441
MDD US Operations, LLC43$1,342
Teva Pharmaceuticals USA, Inc.60$1,304
Biohaven Pharmaceuticals, Inc.67$1,215
Jazz Pharmaceuticals Inc.42$1,130
Amneal Pharmaceuticals LLC70$679
Lundbeck LLC44$659
AstraZeneca(2 entities)24$625
Neurelis, Inc.33$550
SK Life Science, Inc.18$510
Avanir Pharmaceuticals, Inc.17$415
Biohaven Pharmaceutical Holding Company Ltd.34$381
Johnson & Johnson(2 entities)19$366
Axsome Therapeutics, Inc.15$352
Lilly USA, LLC20$348
Tonix Medicines, Inc.31$319
Upsher-smith Laboratories LLC19$318
TG Therapeutics, Inc.5$315
Genentech USA, Inc.2$291
Catalyst Pharmaceuticals, Inc.12$290
Acadia Pharmaceuticals Inc23$282
Impel Pharmaceuticals Inc.26$270
Biogen13$267
Bayer3$261
Neurocrine Biosciences, Inc.14$250
Kyowa Kirin, Inc.13$229
Abbott7$223
Novartis15$222
Grifols USA, LLC5$219
Tanabe Pharma America, Inc.12$194
CSL Behring8$192
Pfizer11$190
Octapharma USA, Inc.10$175
Greenwich Biosciences, Inc.16$167
Azurity Pharmaceuticals, Inc.9$165
Ipsen Biopharmaceuticals, Inc8$154
Novo Nordisk2$149
Supernus Pharmaceuticals, Inc.9$148
Madrigal Pharmaceuticals1$147
Pharmacosmos Therapeutics Inc.1$145
Eisai Inc.6$141
GE HealthCare17$136
Impel Pharmaceuticals LLC7$133
Hologic Sales And Service, LLC1$133
Otsuka America Pharmaceutical, Inc.7$131
Mayne Pharma Commercial LLC1$125
Edwards Lifesciences1$122
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$120
Si-bone, Inc.2$119
Bristol Myers Squibb3$118
Idorsia Pharmaceuticals US Inc1$115
Adamas Pharmaceuticals, Inc.5$114
Gilead1$113
E.r. Squibb & Sons, L.L.C.2$107
Currax Pharmaceuticals LLC5$76
Takeda Pharmaceuticals U.S.A., Inc.5$64
Harmony Biosciences LLC3$63

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,603 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$22,508
Medicare patients
42
Services billed
2,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant78$85,447
Ajovy AutoinjectorFremanezumab-Vfrm46$44,012
Emgality PenGalcanezumab-Gnlm51$38,344
Nurtec OdtRimegepant Sulfate29$34,966
Aimovig AutoinjectorErenumab-Aooe40$29,488
QuliptaAtogepant19$20,477
Ajovy SyringeFremanezumab-Vfrm20$19,794
Sumatriptan Succinate123$16,578
Zolmitriptan33$9,739
Pregabalin108$3,630
Gabapentin232$2,707
Pyridostigmine Bromide39$2,264
Carbidopa-LevodopaCarbidopa/Levodopa31$1,246
Baclofen63$1,139
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$1,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,648$105,92497 claims
PfizerNurtec Odt$190$34,96629 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$679$2,26439 claims
Upsher-smith Laboratories LLCTopiramate$318$61075 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →